CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Dec 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a type of treatment called NK cell therapy for patients with certain blood disorders, specifically myeloproliferative and lymphoproliferative diseases. NK cells are a part of the immune system that can help fight cancer by recognizing and destroying abnormal cells. The trial aims to gather information about how to produce and expand these NK cells from both healthy donors and patients, which could improve treatment options for people with these conditions.

To participate in the trial, you must be over 18 years old and have a myeloproliferative or lymphoproliferative disease. However, if you have certain infections, mental health issues, or disorders that might affect your ability to understand the study, you won’t be eligible. Participants can expect to undergo procedures to collect NK cells and may receive infusions of these cells as part of the treatment. This study is important because it could lead to better therapies that harness the power of the immune system to fight blood cancers and improve patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects over the age of 18 capable of understanding and willing
• • Subjects affected by myelo/lymphoproliferative diseases
• Exclusion Criteria:
• • Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study.
• • Patients affected by lympho or myeloproliferative disorders and Healthy Donors with known acute and chronic viral and bacterial infections :HIV, HCV (Hepatitis C Virus), HBV (Hepatitis B Virus), syphilis